186 research outputs found
Efecto de los compuestos fenólicos extraídos de semillas de girasol sobre la actividad lipoxigenasa nativa.
Extracts of lipoxygenase were obtained from sunflower seeds using 12 different extraction mixtures, and lipoxygenase activity and content of phenolic compounds in the extracts were determined. The content of phenolic compounds was determined as the ratio of optical densities at 320/280nm. Statistical analysis of the results for the extracts showed a significant correlation between the lipoxygenase activity and the OD320nm/OD280nm ratio with r = 0.619. However, after dialysis of the extracts, no correlation was found.Efecto de los compuestos fenólicos extraídos de semillas de girasol sobre la actividad lipoxigenasa nativa. Se obtuvieron extractos de lipoxigenasa de semillas de girasol usando 12 mezclas de extracción diferentes, y se determinó la actividad lipoxigenasa y el contenido en compuestos fenólicos. Este último se llevó a cabo mediante medida de la relación de absorbancias a 320/280nm. El análisis estadístico de los resultados para los extractos mostró una correlación entre la actividad lipoxigenasa y la relación OD320nm/OD280nm con r = 0,619. Sin embargo, después de la diálisis de los extractos, no se observó esta correlación
Bacteriological studies of blood, tissue fluid, lymph and lymph nodes in patients with acute dermatolymphangioadenitis (DLA) in course of ‘filarial’ lymphedema
Filarial lymphedema is complicated by frequent episodes of dermatolymphangioadenitis (DLA). Severe systemic
symptoms during attacks of DLA resemble those of septicemia. The question we asked was whether bacterial isolates
can be found in the peripheral blood of patients during the episodes of DLA. Out of 100 patients referred to us with
‘filarial’ lymphedema 14 displayed acute and five subacute symptoms of DLA. All were on admission blood
microfilariae negative but had a positive test in the past. Blood bacterial isolates were found in nine cases, four acute
(21%) and five subacute (26%). In 10 acute cases blood cultures were found negative. Six blood isolates belonged to
Bacilli, four to Cocci and one was Sarcina. To identify the sites of origin of bacterial dissemination, swabs taken from
the calf skin biopsy wounds and tissue fluid, lymph and lymph node specimens were cultured. Swabs from the calf
skin biopsy wound contained isolates in nine (47%) cases. They were Bacilli in nine, Cocci in three, Acinetobacter and
Erwinia in two cases. Tissue fluid was collected from 10 patients and contained Bacilli in four (40%) and
Staphylococci in three (30%). Lymph was drained in four patients and contained isolates in all samples (100%). They
were Staphylococcus epidermis, xylosus and aureus, Acinetobacter, Bacillus subtilis and Sarcina. Three lymph nodes
were biopsied and contained Staphylococcus chromogenes, xylosus, Enterococcus and Bacillus cereus. In six cases the
same phenotypically defined species of bacteria were found in blood and limb tissues or fluids. In the ‘control’ group of patients with lymphedema without acute or subacute changes all blood cultures were negative. Interestingly, swabs
from biopsy wound of these patients contained isolates in 80%, tissue fluid in 68%, lymph in 70% and lymph nodes
in 58% of cases. In healthy controls, tissue fluid did not contain bacteria, and lymph isolates were found only in 12%
of cases. This study demonstrates that patients with acute episodes of DLA reveal bacteriemia in a high percentage
of cases. Diversity of blood and tissue bacterial isolates in these patients points to a breakdown of the skin immune
barrier in lymphedema and subsequently indiscriminate bacterial colonization of deep tissues and spread to an blood
circulation. © 1999 Elsevier Science B.V. All rights reserved
79. The effectivness of pain treatment with Strontium 89 in patient with osseous metastases
Aimof this study was to assessment of 89 Sr therapy as pain treatment modality in the group of patients with multiple bone metastases.Material and methodsFrom January 2000 to October 2000 in our center were treated 41 patients; 17 – prostate cancer and 24 – breast cancer patients. All patients had applied only one dose of 150 MBq of 89 Sr. Before and follow-up each patient has been evaluated; performance status according to the Karnofsky Scale and paro intensity according the VAS scale. We did not observe any clinical important haematological side effects. The ionisation dosemetric monitoring of the sources and the radioactive refuse were recorded. The radioactive refuse was storage in special container when the activity decreased to the background.ResultsWe noted relief of paro as follow:-“complete” 18 of 41 patients (8-prostate cancer, 10 – breast cancer),-“partial” 12 of 41 patients (3- prostate cancer, 9- breast cancer),-“no effect” 11 of 41 patients (6-prostate cancer, 5- breast cancer).ConclusionsWe suggest that therapy of painful multiple bone metastases with application of 89 Sr is effective nd safe
Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer
The purpose of this study was to determine whether epirubicin, cisplatin and infused 5FU (ECF) improves overall survival (OS) compared to 5FU, etoposide and leucovorin (FELV) in patients with previously untreated advanced biliary cancer in a prospective randomised study. Patients were randomly assigned to receive epirubicin, cisplatin and infused 5FU ECF or bolus 5FU etoposide and leucovorin (FELV). The primary end point was OS with secondary end points of objective response rate (ORR), failure-free survival (FFS), quality of life (QOL) and toxicity. In all, 54 patients were recruited with 27 randomly assigned to each arm. The median OS for ECF was 9.02 months (95% confidence interval (CI): 6.46–11.51) and FELV 12.03 months (95% CI: 9.3–14.7), P=0.2059. Objective response rates were similar for both arms: ECF 19.2% (95% CI: 6.55–39.3); FELV 15% (95% CI: 3.2–37.9), P=0.72. There was significantly increased grade 3/4 neutropenia with FELV vs ECF (53.8 vs 29.5%, respectively, P=0.020). Symptom resolution was impressive for both regimens. This is the largest reported randomised study to date in this setting. ECF did not improve OS compared to FELV, but was associated with less acute toxicity. These data suggest that chemotherapy can prolong OS and achieve good symptomatic relief in advanced biliary cancer
Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. However, treatment options are limited and often inefficient. The aim of this study was to determine current survival rates for patients diagnosed with HCC and to identify prognostic factors, which will help in choosing optimal therapies for individual patients. A retrospective analysis of medical records was performed on 389 patients who were identified through the central tumour registry at our institution from 1998 to 2003. Clinical parameters, treatments received and survival curves from time of diagnosis were analysed. Overall median survival was 11 months. Liver cirrhosis was diagnosed in 80.5% of all patients. A total of 170 patients received transarterial chemoembolisation (TACE) and/or percutaneous ethanol injections (PEI) with a median survival rate of 16 months for patients receiving TACE, 11 months for patients receiving PEI and 24 months for patients receiving TACE followed by PEI. Independent negative prognostic parameters for survival were the presence of portal vein thrombosis, advanced liver cirrhosis (Child–Pugh score B or C) and a score of >2. This study will help to estimate survival rates for patients with HCC according to their clinical status at diagnosis and the treatments received
Frontal sinuses and human evolution
The frontal sinuses are cavities inside the frontal bone located at the junction between the face and the cranial vault and close to the brain. Despite a long history of study, understanding of their origin and variation through evolution is limited. This work compares most hominin species? holotypes and other key individuals with extant hominids. It provides a unique and valuable perspective of the variation in sinuses position, shape, and dimensions based on a simple and reproducible methodology. We also observed a covariation between the size and shape of the sinuses and the underlying frontal lobes in hominin species from at least the appearance of Homo erectus. Our results additionally undermine hypotheses stating that hominin frontal sinuses were directly affected by biomechanical constraints resulting from either chewing or adaptation to climate. Last, we demonstrate their substantial potential for discussions of the evolutionary relationships between hominin species. Variation in frontal sinus shape and dimensions has high potential for phylogenetic discussion when studying human evolution
PaleoBRAIN: Ressusciter le cerveau d'Homo erectus et des Néandertaliens = PaleoBRAIN: Bringing the brain of Homo erectus and Neandertals back to life
Adenoviral Vector Driven by a Minimal Rad51 Promoter Is Selective for p53-Deficient Tumor Cells
Background: The full length Rad51 promoter is highly active in cancer cells but not in normal cells. We therefore set out to assess whether we could confer this tumor-selectivity to an adenovirus vector. Methodology/Principal Findings: Expression of an adenovirally-vectored luciferase reporter gene from the Rad51 promoter was up to 50 fold higher in cancer cells than in normal cells. Further evaluations of a panel of truncated promoter mutants identified a 447 bp minimal core promoter element that retained the full tumor selectivity and transcriptional activity of the original promoter, in the context of an adenovirus vector. This core Rad51 promoter was highly active in cancer cells that lack functional p53, but less active in normal cells and in cancer cell lines with intact p53 function. Exogenous expression of p53 in a p53 null cell line strongly suppressed activity of the Rad51 core promoter, underscoring the selectivity of this promoter for p53-deficient cells. Follow-up experiments showed that the p53-dependent suppression of the Rad51 core promoter was mediated via an indirect, p300 coactivator dependent mechanism. Finally, transduction of target cells with an adenovirus vector encoding the thymidine kinase gene under transcriptional control of the Rad51 core promoter resulted in efficient killing of p53 defective cancer cells, but not of normal cells, upon addition of ganciclovir. Conclusions/Significance: Overall, these experiments demonstrated that a small core domain of the Rad51 promoter ca
A call to caution when hydroxychloroquine is given to elderly COVID-19 patients.
INTRODUCTION: Hydroxychloroquine use in COVID-19 patients was widespread and uncontrolled until recently. Patients vulnerable to severe COVID-19 are at risk for hydroxychloroquine interactions with comorbidities and co-medications contributing to detrimental, including fatal adverse treatment effects. METHODS: This is a retrospective survey of health conditions and co-medications of COVID-19 patients who were pre-screened for enrolment into a randomized, double-blind, placebo-controlled hydroxychloroquine multicenter trial. RESULTS: Our survey involved 305 patients (median age 71 (IQR: 59-81) years). The majority of patients (N = 279, 92%) considered for inclusion into the clinical trial were not eligible mainly due to safety concerns caused by health conditions or co-medications. Most common were QT prolonging drugs (N = 188, 62%) and hematologic/hemato-oncologic diseases (N = 39, 13%) which prohibited the administration of hydroxychloroquine in our clinical trial. Additionally, 165 (54%) patients had health conditions and 167 (55%) were on co-medications that did not prohibit hydroxychloroquine treatment but had a risk of adverse interactions with hydroxychloroquine. Most common were diabetes (N = 86, 28%), renal insufficiency (N = 69, 23%) and heart failure (N = 58, 19%). CONCLUSION: The majority of hospitalized COVID-19 patients had health conditions or took co-medications precluding safe treatment with hydroxychloroquine. Therefore, especially in elderly, hydroxychloroquine should be administered with extreme caution and only in clinical trials
- …